TP53 and neoplasm: By contrast, KPC mice develop hypovascular mPDACs that have minimal blood flow [17, 46, 52], KTC mice (oncogenic Kras with deletion of the type II TGF-β receptor) exhibit tumor angiogenesis [33], whereas in KPfl/+CY mice (oncogenic Kras and heterozygous p53 loss) exhibit suppressed angiogenesis [20].